JP2017529094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529094A5 JP2017529094A5 JP2017522732A JP2017522732A JP2017529094A5 JP 2017529094 A5 JP2017529094 A5 JP 2017529094A5 JP 2017522732 A JP2017522732 A JP 2017522732A JP 2017522732 A JP2017522732 A JP 2017522732A JP 2017529094 A5 JP2017529094 A5 JP 2017529094A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- braf
- nras
- mutation
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 20
- 230000035772 mutation Effects 0.000 claims 19
- 108020004707 nucleic acids Proteins 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 18
- 150000007523 nucleic acids Chemical class 0.000 claims 18
- 108091034117 Oligonucleotide Proteins 0.000 claims 17
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 17
- 239000000523 sample Substances 0.000 claims 17
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 102100039788 GTPase NRas Human genes 0.000 claims 12
- 239000012824 ERK inhibitor Substances 0.000 claims 11
- 102000043136 MAP kinase family Human genes 0.000 claims 11
- 108091054455 MAP kinase family Proteins 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 11
- 238000009396 hybridization Methods 0.000 claims 10
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 9
- 229940125431 BRAF inhibitor Drugs 0.000 claims 6
- 101150073096 NRAS gene Proteins 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 6
- 239000013615 primer Substances 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000003321 amplification Effects 0.000 claims 4
- 101150048834 braF gene Proteins 0.000 claims 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims 4
- 239000004474 valine Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
- 230000004043 responsiveness Effects 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- 239000003155 DNA primer Substances 0.000 claims 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 150000003384 small molecules Chemical group 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical group O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims 1
- 102000050152 human BRAF Human genes 0.000 claims 1
- 102000047526 human NRAS Human genes 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002853 nucleic acid probe Substances 0.000 claims 1
- 102220197775 rs1057519695 Human genes 0.000 claims 1
- 102200124924 rs11554290 Human genes 0.000 claims 1
- 102200124923 rs121913254 Human genes 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176944.8 | 2014-07-14 | ||
| EP14176944 | 2014-07-14 | ||
| PCT/EP2015/065986 WO2016008853A1 (en) | 2014-07-14 | 2015-07-13 | Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529094A JP2017529094A (ja) | 2017-10-05 |
| JP2017529094A5 true JP2017529094A5 (enExample) | 2018-07-05 |
| JP7036594B2 JP7036594B2 (ja) | 2022-03-15 |
Family
ID=51210291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522732A Active JP7036594B2 (ja) | 2014-07-14 | 2015-07-13 | Ｂｒａｆ陽性癌を患っている患者を、ｂｒａｆ阻害剤に対する非レスポンダーであると及びｍａｐｋ／ｅｒｋ阻害剤に対するレスポンダーであると同定する手段及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190194757A1 (enExample) |
| EP (1) | EP3169797B2 (enExample) |
| JP (1) | JP7036594B2 (enExample) |
| CN (1) | CN107148481A (enExample) |
| CA (1) | CA2953732C (enExample) |
| ES (1) | ES2751925T5 (enExample) |
| WO (1) | WO2016008853A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX393780B (es) | 2017-01-17 | 2025-03-24 | Heparegenix Gmbh | Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos |
| WO2018213302A1 (en) * | 2017-05-16 | 2018-11-22 | Biomed Valley Discoveries, Inc. | Compositions and methods for treating cancer with atypical braf mutations |
| CN112795647B (zh) * | 2019-11-14 | 2022-08-16 | 北京肿瘤医院(北京大学肿瘤医院) | 一种肿瘤标志物及其应用 |
| CN111020033A (zh) * | 2019-12-24 | 2020-04-17 | 中山大学达安基因股份有限公司 | 多重检测braf基因突变的试剂盒及方法 |
| EP4359781A4 (en) * | 2021-06-23 | 2025-05-14 | Royal Melbourne Institute of Technology | CONDUCTOMETRIC SENSOR FOR DETECTING A NUCLEIC ACID AND ITS DETECTION METHOD |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120252015A1 (en) * | 2011-02-18 | 2012-10-04 | Bio-Rad Laboratories | Methods and compositions for detecting genetic material |
| CN103911428B (zh) * | 2009-03-27 | 2016-02-24 | 生命技术公司 | 用于检测等位基因变体的方法、组合物和试剂盒 |
| US20130315934A1 (en) * | 2010-10-28 | 2013-11-28 | Yale University | Methods and Compositions for Assessing and Treating Cancer |
| WO2012061683A2 (en) | 2010-11-05 | 2012-05-10 | Glaxosmithkline Llc | Methods for treating cancer |
| WO2012068468A1 (en) * | 2010-11-19 | 2012-05-24 | Glaxosmithkline Llc | Method of treatment with braf inhibitor |
| WO2012068562A2 (en) * | 2010-11-19 | 2012-05-24 | The Regents Of The University Of California | Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas |
| WO2014009318A1 (en) * | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer |
| WO2014009319A1 (en) * | 2012-07-11 | 2014-01-16 | Boehringer Ingelheim International Gmbh | Indolinone derivatives anticancer compounds |
| WO2014052613A2 (en) | 2012-09-26 | 2014-04-03 | Insight Genetics, Inc. | Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers |
-
2015
- 2015-07-13 CN CN201580038260.0A patent/CN107148481A/zh active Pending
- 2015-07-13 EP EP15734713.9A patent/EP3169797B2/en active Active
- 2015-07-13 US US15/326,344 patent/US20190194757A1/en not_active Abandoned
- 2015-07-13 CA CA2953732A patent/CA2953732C/en active Active
- 2015-07-13 JP JP2017522732A patent/JP7036594B2/ja active Active
- 2015-07-13 WO PCT/EP2015/065986 patent/WO2016008853A1/en not_active Ceased
- 2015-07-13 ES ES15734713T patent/ES2751925T5/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robbins et al. | Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors | |
| JP2013501523A5 (enExample) | ||
| Morgan et al. | Genetic diagnosis of familial breast cancer using clonal sequencing | |
| JP2017529094A5 (enExample) | ||
| JP2017510244A5 (enExample) | ||
| JP2010508042A5 (enExample) | ||
| JP2019536456A5 (enExample) | ||
| JP2009077712A5 (enExample) | ||
| JP2011511949A5 (enExample) | ||
| CN109837340B (zh) | 用于肺癌无创诊断的外周血基因标记物 | |
| JP2010518811A5 (enExample) | ||
| Wagner et al. | ALCAM and CD6—multiple sclerosis risk factors | |
| WO2013188840A1 (en) | Compositions and methods for sensitive mutation detection in nucleic acid molecules | |
| JP2016509833A5 (enExample) | ||
| JP2014500028A5 (enExample) | ||
| JP6531312B2 (ja) | Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法 | |
| JP2020521440A5 (enExample) | ||
| JP2016533708A5 (enExample) | ||
| CN102312001A (zh) | 多重pcr-反向斑点杂交技术检测结核分枝杆菌耐药性的方法 | |
| Neavin et al. | Single Nucleotide Polymorphisms at a Distance from Aryl Hydrocarbon Receptor (AHR) Binding Sites Influence AHR Ligand–Dependent Gene Expression | |
| CN104531875A (zh) | 一种MyD88基因突变荧光定量PCR检测试剂盒及检测方法 | |
| JP2015505669A5 (enExample) | ||
| GB2597895A (en) | Chromosome conformation markers of prostate cancer and lymphoma | |
| JP2017143810A5 (enExample) | ||
| Alcaraz-López et al. | Assessment of candidate biomarkers to detect resistance to Mycobacterium bovis in Holstein-Friesian cattle |